Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00806546 · ClinicalTrials.gov registry record · Phase 3
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
A Phase 3 study, sponsored by NuPathe.
- Completed
- Registry status
- Phase 3
- Development phase
- 514
- Enrollment target
NCT00806546 is a Phase 3 study that has completed, run by NuPathe. The registered enrollment target is 514 participants.
The verdict
NCT00806546, a Phase 3 study, has completed, sponsored by NuPathe.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 514 participants
- Enrollment target
Study Summary
This study will use an open-label design to evaluate the safety of NP101. Adult subjects who meet the enrollment criteria will be treated with NP101 (sumatriptan succinate iontophoretic transdermal patch) for acute migraine attacks over a 12 month period.
Interventions
- DRUG NP101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 514 participants |
| Start Date | 2009-02 |
| Est. Completion | 2011-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00806546
The ClinicalTrials.gov registry entry for NCT00806546 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 514 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NuPathe, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NP101 is the first listed.
NCT00806546 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00806546 about?
NCT00806546 is a clinical study titled "An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months". This study will use an open-label design to evaluate the safety of NP101. Adult subjects who meet the enrollment criteria will be treated with NP101 (sumatriptan succinate iontophoretic transdermal patch) for acute migraine attacks over a 12 month period.
What is the current status of trial NCT00806546?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 514 participants. The study started on 2009-02. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00806546?
The interventions under investigation include: NP101 (DRUG).
Who is sponsoring clinical trial NCT00806546?
This trial is sponsored by NuPathe, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.